OFORTA
LOE ApproachingNDAORALTABLET
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OFORTA is an oral small-molecule tablet approved by Sanofi in December 2008. The mechanism of action and specific indication are not publicly disclosed in available data. Patient population and therapeutic area remain undetermined without additional clinical context.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team consolidation and transition planning underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate product is not actively hiring for new roles; existing teams are likely managing steady-state operations. Career movement on OFORTA suggests supporting a legacy brand through LOE transition rather than growth-stage opportunity.
Brand ManagerSales Representative
Worked on OFORTA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.